Related references
Note: Only part of the references are listed.Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients
Thomas S. Y. Chan et al.
ANNALS OF HEMATOLOGY (2014)
Paradoxical Growth of Candida albicans in the Presence of Caspofungin Is Associated with Multiple Cell Wall Rearrangements and Decreased Virulence
Cristina Rueda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Positions and Numbers of FKS Mutations in Candida albicans Selectively Influence In Vitro and In Vivo Susceptibilities to Echinocandin Treatment
M. Lackner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates
Gregory A. Eschenauer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin
Fernando Cesar Bizerra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Tissue Penetration of Antifungal Agents
Timothy Felton et al.
CLINICAL MICROBIOLOGY REVIEWS (2014)
Impact of Therapeutic Strategies on the Prognosis of Candidemia in the ICU
Mireia Puig-Asensio et al.
CRITICAL CARE MEDICINE (2014)
Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms
Nicolas Delattin et al.
FUTURE MEDICINAL CHEMISTRY (2014)
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality
Matteo Bassetti et al.
INTENSIVE CARE MEDICINE (2014)
Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study
Wei Liu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria
Michael A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2014)
Amphotericin forms an extramembranous and fungicidal sterol sponge
Thomas M. Anderson et al.
NATURE CHEMICAL BIOLOGY (2014)
Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?
A. Espinel-Ingroff et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-albicans Candida Biofilms
K. F. Mitchell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin
A. Fekkar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical
Arnaldo Lopes y Colombo et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2013)
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Barbara D. Alexander et al.
CLINICAL INFECTIOUS DISEASES (2013)
Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal
S. Leroux et al.
CLINICAL MICROBIOLOGY AND INFECTION (2013)
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
Maiken C. Arendrup et al.
DRUG RESISTANCE UPDATES (2013)
Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity
Richard J. Hamill
DRUGS (2013)
Mechanisms of Candida biofilm drug resistance
Heather T. Taff et al.
FUTURE MICROBIOLOGY (2013)
Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)
M. T. Montagna et al.
INFECTION (2013)
Candidaemia in the non-neutropenic patient: A critique of the guidelines
A. Deshpande et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases
Yanan Zhao et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain
Matteo Bassetti et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Practical considerations on current guidelines for the management of non-neutropenic adult patients with candidaemia
A. Gloeckner et al.
MYCOSES (2013)
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Benjamin Matteson Vincent et al.
PLOS BIOLOGY (2013)
Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment
Michael A. Pfaller
AMERICAN JOURNAL OF MEDICINE (2012)
Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo
Keunsook K. Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
ECIL 3-2009 update guidelines for antifungal management
L. Castagna et al.
BONE MARROW TRANSPLANTATION (2012)
Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
David R. Andes et al.
CLINICAL INFECTIOUS DISEASES (2012)
Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011
Angela Ahlquist Cleveland et al.
CLINICAL INFECTIOUS DISEASES (2012)
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
O. A. Cornely et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
The changing epidemiology of healthcare-associated candidemia over three decades
Daniel Diekema et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence
Florent Morio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Antifungal susceptibility of Candida albicans in biofilms
Selma Tobudic et al.
MYCOSES (2012)
Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms
Margarida Martins et al.
MYCOSES (2012)
Amphotericin primarily kills yeast by simply binding ergosterol
Kaitlyn C. Gray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance
Sonia Silva et al.
FEMS MICROBIOLOGY REVIEWS (2012)
Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients
Olivier Lortholary et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice
Selene Ferrari et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
M. A. Pfaller et al.
DRUG RESISTANCE UPDATES (2011)
Effects of Fluconazole on the Secretome, the Wall Proteome, and Wall Integrity of the Clinical Fungus Candida albicans
Alice G. Sorgo et al.
EUKARYOTIC CELL (2011)
Current perspectives on echinocandin class drugs
David S. Perlin
FUTURE MICROBIOLOGY (2011)
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Antifungal use influences Candida species distribution and susceptibility in the intensive care unit
Pierre Fournier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy
Markus Ruhnke et al.
MYCOSES (2011)
Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Nicole Robbins et al.
PLOS PATHOGENS (2011)
Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient
Florence Chapeland-Leclerc et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients
Yves Cohen et al.
CRITICAL CARE MEDICINE (2010)
Epidemiology of Invasive Mycoses in North America
Michael A. Pfaller et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2010)
Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature
Florent Morio et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2010)
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida Time for harmonization of CLSI and EUCAST broth microdilution methods
M. A. Pfaller et al.
DRUG RESISTANCE UPDATES (2010)
Fungal echinocandin resistance
Louise A. Walker et al.
FUNGAL GENETICS AND BIOLOGY (2010)
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Hsin-Yun Sun et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Breakthrough Invasive Candidiasis in Patients on Micafungin
Christopher D. Pfeiffer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Rapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia
Jesus Guinea et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Comparison of the Vitek 2 Antifungal Susceptibility System with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest Techniques for In Vitro Detection of Antifungal Resistance in Yeast Isolates
Manuel Cuenca-Estrella et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
PKC Signaling Regulates Drug Resistance of the Fungal Pathogen Candida albicans via Circuitry Comprised of Mkc1, Calcineurin, and Hsp90
Shantelle L. LaFayette et al.
PLOS PATHOGENS (2010)
Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Nonsense and Missense Mutations in FCY2 and FCY1 Genes Are Responsible for Flucytosine Resistance and Flucytosine-Fluconazole Cross-Resistance in Clinical Isolates of Candida lusitaniae
Martine Florent et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing
Huiping Wang et al.
BMC MICROBIOLOGY (2009)
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
Leonard A. Mermel et al.
CLINICAL INFECTIOUS DISEASES (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Liposomal Amphotericin B A Review of its Use as Empirical Therapy in Febrile Neutropenia and in the Treatment of Invasive Fungal Infections
Marit D. Moen et al.
DRUGS (2009)
Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation
Dominique Sanglard et al.
FEMS YEAST RESEARCH (2009)
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment
Benoit P. Guery et al.
INTENSIVE CARE MEDICINE (2009)
Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata
Silvia Polakova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility
Guillermo Garcia-Effron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses study group and European Organization for Research and Treatment of Cancer consensus criteria
Brahm H. Segal et al.
CLINICAL INFECTIOUS DISEASES (2008)
Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit
Jennifer K. Chow et al.
CLINICAL INFECTIOUS DISEASES (2008)
Resistance to antifungal agents: Mechanisms and clinical impact
Zeina A. Kanafani et al.
CLINICAL INFECTIOUS DISEASES (2008)
EUCAST Definitive Document EDef 7.1:: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts
J. L. Rodriguez-Tudela et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy
Nabil Kabbara et al.
HAEMATOLOGICA (2008)
Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates
Alix Coste et al.
EUKARYOTIC CELL (2007)
Acquired resistance to echinocandins in Candida albicans:: case report and review
Marie-Therese Baixench et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals
Hyun Woo Choi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Epidemiology of invasive candidiasis: a persistent public health problem
M. A. Pfaller et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Candida rugosa, an emerging fungal pathogen with resistance to azoles:: Geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii
Emilia Canton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy
Morgan Hakki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome
BJ Park et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient
M Krogh-Madsen et al.
CLINICAL INFECTIOUS DISEASES (2006)
A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans
A Coste et al.
GENETICS (2006)
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan -: art. no. 99
YL Yang et al.
BMC INFECTIOUS DISEASES (2005)
Establishing surrogate markers for fluconazole resistance in Candida albicans
S Park et al.
MICROBIAL DRUG RESISTANCE (2005)
Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness
JB Anderson
NATURE REVIEWS MICROBIOLOGY (2005)
Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole:: a longitudinal study
H Lamfon et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Comparative evaluation of Sensititre® YeastOne vs. the NCCLS M27A protocol and E-test for antifungal susceptibility testing of yeasts
G Lombardi et al.
MYCOSES (2004)
Antifungal agents: mechanisms of action
FC Odds et al.
TRENDS IN MICROBIOLOGY (2003)
Calcineurin A of Candida albicans:: involvement in antifungal tolerance, cell morphogenesis and virulence
D Sanglard et al.
MOLECULAR MICROBIOLOGY (2003)
Molecular diversity and routes of colonization of Candida albicans in a surgical intensive care unit, as studied using microsatellite markers
F Stéphan et al.
CLINICAL INFECTIOUS DISEASES (2002)
In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.:: Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods
MA Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species
E Chryssanthou et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Antifungal susceptibility of Candida biofilms:: Unique efficacy of amphotericin B lipid formulations and echinocandins
DM Kuhn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Antifungal drug resistance of pathogenic fungi
DP Kontoyiannis et al.
LANCET (2002)